Which generation of targeted drug is adagrasib? What disease does it treat?

Adagrasib (Adagrasib) is a new generation of targeted drugs, specifically an inhibitor targeting the KRAS G12C mutation. The KRAS G12C mutation is a common genetic mutation in various cancers, especially non-small cell lung cancer (NSCLC). This mutation leads to abnormal activation of the KRAS protein, which promotes tumor growth and progression.

Adagrasiib is mainly used to treat non-small cell lung cancer that has spread to other parts of the body or cannot be removed with surgery. It is particularly suitable for patients whose tumors have an abnormal KRAS G12C gene and have received at least one prior treatment. The emergence of this innovative drug provides new treatment strategies for these patients.

In addition to non-small cell lung cancer, adagrasib has also shown potential in treating colon or rectal cancer (CRC). When used in combination with the drug cetuximab, it could provide a treatment option for patients whose tumors have spread to other parts of the body, cannot be removed by surgery, and whose tumors have the KRAS G12C mutation. This combination therapy is particularly suitable for patients who have previously received certain chemotherapy drugs.

The mechanism of action of adagrasib is to irreversibly bind toKRAS G12C mutant, thereby inhibiting its activity and achieving the effect of inhibiting the growth and spread of cancer cells. This highly specific targeted treatment method not only improves the accuracy of treatment, but also reduces damage to normal cells.

In summary, adagrasib, as a new generation ofKRAS G12C mutation-targeting drugs, provides a new treatment option for patients with non-small cell lung cancer and colon or rectal cancer. Its unique pharmacological effects and significant therapeutic effects make it have broad application prospects in the field of cancer treatment.